Tim Illidge

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla et al. · Cancer Research · 2014 · 1.3K citations · Full text

Life Sciences, Immunology, Oncology +17

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2012 · 990 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

John Radford, Tim Illidge, Nicholas Counsell et al. · New England Journal of Medicine · 2015 · 750 citations · Full text

Medicine, Oncology, Radiology +16

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak et al. · Journal of Clinical Oncology · 2003 · 587 citations · Full text

Medicine, Oncology, Radiation Oncology +17